At the news
? NEUTRALIMPACT 2/10 6-K filed Aug 18, 2026 at 06:12 ET
HUTCHMED filed a routine 6-K disclosing that its Chairman, Dr. Dan Eldar, was formerly a director of S.D. Sight Diagnostics Ltd., which entered insolvency proceedings in Israel. The filing explicitly states the insolvency does not involve HUTCHMED or its operations, and the amount involved (~$1M) is immaterial relative to HUTCHMED's $2.1B market cap. This is a purely administrative AIM Rule disclosure with no financial or operational impact on the company.
- Chairman Dr. Dan Eldar was a director of S.D. Sight Diagnostics from Dec 2018 to Mar 2026.
- S.D. Sight entered insolvency proceedings in Israel; a trustee was appointed on May 28, 2026.
- The amount involved is approximately NIS 3,057,876 (~US$1,019,292).
- Neither S.D. Sight nor Hutchison Water Israel E.P.C Ltd (which holds ~9.98% of S.D. Sight) is part of HUTCHMED.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access